TY - JOUR
T1 - A brief history of "Alzheimer disease"
T2 - Multiple meanings separated by a common name
AU - Knopman, David S.
AU - Petersen, Ronald C.
AU - Jack, Clifford R.
N1 - Funding Information:
D. Knopman serves on a Data Safety Monitoring Board for the DIAN study; is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California; and receives research support from the NIH/NIA. R. Jack receives research support from the NIH/ NIA and the Alexander Family Alzheimer’s Disease Research Professorship of the Mayo Foundation. C. Petersen serves on data monitoring committees for Janssen Alzheimer Immunotherapy and is a consultant for Biogen, Roche, Merck, and Genentech, Inc.; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH/NIA. Go to Neurology.org/N for full disclosures.
Funding Information:
Supported by NIH grants P50 AG16574, U01 AG06786, R01 AG034676, R01 AG011378, and R01 AG41851.
Publisher Copyright:
© 2019 American Academy of Neurology.
PY - 2019/5/28
Y1 - 2019/5/28
N2 - The field of Alzheimer disease (AD) has a nosologic problem: The diagnostic label "Alzheimer disease" has several distinctive meanings. The term probable AD was introduced in 1984 to designate a clinically diagnosed acquired and progressive amnestic dementia for which there was no evidence for another etiology. Probable AD represented a clinicopathologic entity that assumed a specific and sensitive linkage between amnestic dementia and the neuropathology of β-amyloid-containing neuritic plaques and tau-containing neurofibrillary tangles. The clinicopathologic model represented by probable AD was adapted in abbreviated form for population-based studies and general clinical practice, although the uncertainty connoted by "probable" was often overlooked. Representing the growing public awareness of later life cognitive impairment, a vernacular meaning of AD arose out of the clinicopathologic model in which AD represented all dementia not due to another clinically apparent cause. In contrast, by the 1990s, neuropathologists settled on a definition of AD based entirely on a sufficient burden of neuritic plaques and neurofibrillary tangles at postmortem examination, regardless of antemortem clinical status. In the last decade, the availability of fluid and imaging biomarkers that measure β-amyloid and tau abnormalities has enabled antemortem pathobiological diagnoses, highlighting the divide between the clinicopathologic model, the vernacular usage, and the pathobiological models. Each definition has value. However, the meanings of AD as defined by each of these models are not interchangeable. The pathobiological one is the only one that is unambiguous.
AB - The field of Alzheimer disease (AD) has a nosologic problem: The diagnostic label "Alzheimer disease" has several distinctive meanings. The term probable AD was introduced in 1984 to designate a clinically diagnosed acquired and progressive amnestic dementia for which there was no evidence for another etiology. Probable AD represented a clinicopathologic entity that assumed a specific and sensitive linkage between amnestic dementia and the neuropathology of β-amyloid-containing neuritic plaques and tau-containing neurofibrillary tangles. The clinicopathologic model represented by probable AD was adapted in abbreviated form for population-based studies and general clinical practice, although the uncertainty connoted by "probable" was often overlooked. Representing the growing public awareness of later life cognitive impairment, a vernacular meaning of AD arose out of the clinicopathologic model in which AD represented all dementia not due to another clinically apparent cause. In contrast, by the 1990s, neuropathologists settled on a definition of AD based entirely on a sufficient burden of neuritic plaques and neurofibrillary tangles at postmortem examination, regardless of antemortem clinical status. In the last decade, the availability of fluid and imaging biomarkers that measure β-amyloid and tau abnormalities has enabled antemortem pathobiological diagnoses, highlighting the divide between the clinicopathologic model, the vernacular usage, and the pathobiological models. Each definition has value. However, the meanings of AD as defined by each of these models are not interchangeable. The pathobiological one is the only one that is unambiguous.
UR - http://www.scopus.com/inward/record.url?scp=85066966618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066966618&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000007583
DO - 10.1212/WNL.0000000000007583
M3 - Review article
C2 - 31028129
AN - SCOPUS:85066966618
SN - 0028-3878
VL - 92
SP - 1053
EP - 1059
JO - Neurology
JF - Neurology
IS - 22
ER -